MDS-MSC inhibit the endocytosis of monocyte derived DCs.

<p>DCs <b>(5×10⁵)</b> were incubated in medium with FITC-labeled dextran at a concentration of 1 mg/ml in the presence of MSC <b>(5×10⁴)</b> at day 7. After an incubation period of 60 min at 37°C (green line) or 4°C as a control (gray line), cells were harvested and analyzed by FACS.Numbers in histograms indicate the mean fluorescence of each cell population. Results are expressed as mean±SD of triplicates of 5 separate experiments. *P≤0.05.</p

MDS-MSC reduce IL-12 secretion of monocyte-derived DCs.

<p>DCs <b>(1×10⁶)</b> obtained from monocytes after 7 days of induction with GM-CSF plus IL-4 were stimulated by LPS for an additional 48 hours with or without MSC coculture, and then cell-free supernatants were collected and quantified by ELISA for IL-12 production. Results are expressed as mean±SD of triplicates of 5 separate experiments. *P≤0.05.</p

TGFβ1 plays a key role in the MSC-mediated inhibition of DCs differentiation and functions.

<p>Monocytes were cultured with GM-CSF and IL-4 to induce differentiation into DCs. Cultures were performed either in the absence or in the presence of MSC. In addition, anti-rhTGF-β1, or anti-rhIL-6, or 1-methyltryptophan, IDO inhibitor, or indomethacin, PGE2 inhibitor, or PBIT, NO inhibitor was added to monocyte-MSC cocultures. After 5 days, expression of CD1a (A) and CD14 (B) in cells cultured under the described was performed to check DCs differentiation. (C) IL-12 was measured in culture supernatants after 48-hour stimulation with LPS of monocyte-derived cells cultured for 7 days with GM-CSF and IL-4 either in the absence or in the presence of MSC., anti-rhTGF-β1, or anti-rhIL-6, or 1-methyltryptophan, IDO inhibitor, or indomethacin, PGE2 inhibitor, or PBIT, NO inhibitor was added at the beginning of the culture. DCs obtained from monocytes after 7 days of induction with GM-CSF plus IL-4 were stimulated by LPS for an additional 48 hours without MSC coculture. (D) anti-rhTGF-β1, or anti-rhIL-6, or 1-methyltryptophan, IDO inhibitor, or indomethacin, PGE2 inhibitor, or PBIT, NO inhibitor was added at the beginning of MLR coculture. T-lymphocyte proliferation was assessed by [3H]-thymidine incorporation. Data are expressed as mean±SD of triplicates of 5 separate experiments. *P≤0.05.</p

MDS-MSC inhibit the capability of inducing T-cell response in MLR of monocyte-derived DCs.

<p>mDCs <b>(1×10⁵)</b> were irradiated and used to induce allogeneic T cells (10⁶ responder cells/well) with or without MSC <b>(1×10⁵)</b> in the MLR culture. After culture for 5 days, T-cell proliferation was evaluated by adding 3H-thymidine to each well 18 h before the cultures were terminated. Results are expressed as mean±SD of triplicates of 5 separate experiments. *P≤0.05.</p

Additional file 1: of Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Methods (DOCX 16 kb

Additional file 2: Table S1. of Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

Patients’ baseline characteristics (DOCX 16 kb